As beta‐1 adrenergic receptor (β1AR) blockers are dominantly used in the clinic to treat cardiovascular diseases, we aimed to assess the therapeutic benefit of targeting either the β1AR, the beta‐2 adrenergic receptor (β2AR), or both βARs as a therapeutic option for multiple myeloma patients. This evidence concerns the gene CTBP1 and AL amyloidosis.